Gastrointestinal Stromal Tumor (GIST) Therapeutics Market Size, Share, Trends, Growth Outlook

Gastrointestinal Stromal Tumor (GIST) Therapeutics Market is estimated to increase at a growth rate of 6.4% CAGR over the forecast period from 2024 to 2030.

The global Gastrointestinal Stromal Tumor (GIST) Therapeutics Market Study analyzes and forecasts the market size across 6 regions and 24 countries for diverse segments including By Drug (Imatinib, Ripretinib, Crenolanib, Regorafenib, Avapritinib, Sunitinib, Entrectinib, Larotrectinib), By Therapy (Targeted therapy, Chemotherapy, Radiation therapy ), By Distribution Channel (Hospital pharmacies, Retail pharmacies, Online pharmacies), By Route of Administration (Oral, Parenteral).

An Introduction to Gastrointestinal Stromal Tumor (GIST) Therapeutics Market in 2024

The Gastrointestinal Stromal Tumor (GIST) Therapeutics Market focuses on targeted therapies, molecular inhibitors, and treatment options specifically designed for gastrointestinal stromal tumors, a type of soft tissue sarcoma that affects the digestive system, particularly the stomach and intestines. This market includes tyrosine kinase inhibitors (TKIs), immunotherapy agents, surgical interventions, and adjuvant therapies that aim to inhibit tumor growth, prevent metastasis, and improve outcomes for patients with GIST.

Gastrointestinal Stromal Tumor (GIST) Therapeutics Market Competitive Landscape

The global Gastrointestinal Stromal Tumor (GIST) Therapeutics Industry is highly competitive with a large number of companies focusing on niche market segments. Amidst intense competitive conditions, Gastrointestinal Stromal Tumor (GIST) Therapeutics Companies are investing in new product launches and strengthening distribution channels. Key companies operating in the Gastrointestinal Stromal Tumor (GIST) Therapeutics Industry include- AB Science SA, AROG Pharmaceuticals Inc, Bayer AG, Blueprint Medicines Corp, Bristol Myers Squibb Co., Daiichi Sankyo Co. Ltd, Deciphera Pharmaceuticals Inc, Ipsen Pharma, Mendus AB, Novartis AG, Pfizer Inc, Sun Pharmaceutical Industries Ltd, Theseus Pharmaceuticals., Xencor Inc.

Gastrointestinal Stromal Tumor (GIST) Therapeutics Market Trend: Advancements in Targeted Therapies

A significant trend in the gastrointestinal stromal tumor (GIST) therapeutics market is the advancements in targeted therapies specifically designed to inhibit oncogenic signaling pathways implicated in GIST pathogenesis, such as KIT and PDGFRA mutations. Targeted therapies, including tyrosine kinase inhibitors (TKIs) like imatinib, sunitinib, and regorafenib, have revolutionized the treatment landscape for GIST, offering improved progression-free survival and quality of life for patients with unresectable or metastatic disease. This trend reflects the growing understanding of the molecular mechanisms driving GIST and the development of precision medicine approaches tailored to individual patients' genetic profiles, driving market innovation and investment in targeted therapeutic strategies for GIST management.

Gastrointestinal Stromal Tumor (GIST) Therapeutics Market Driver: Increasing Incidence of Gastrointestinal Stromal Tumors

A key driver in the gastrointestinal stromal tumor (GIST) therapeutics market is the increasing incidence of GIST globally, driven by factors such as aging populations, improved diagnostic techniques, and increased awareness of the disease. GIST represents the most common mesenchymal tumor of the gastrointestinal tract, with a subset of cases associated with mutations in the KIT or PDGFRA genes. As the incidence of GIST continues to rise, particularly in older adults, there is a growing demand for effective therapeutic interventions that can control tumor growth, delay disease progression, and prolong survival in patients with advanced or recurrent GIST. This driver underscores the need for continued research and development efforts to expand the treatment armamentarium for GIST and address unmet medical needs in this patient population, driving market demand for GIST therapeutics.

Gastrointestinal Stromal Tumor (GIST) Therapeutics Market Opportunity: Development of Combination Therapies

One Market Opportunity in the gastrointestinal stromal tumor (GIST) therapeutics market lies in the development of combination therapies that synergistically target multiple signaling pathways implicated in GIST pathogenesis, such as KIT, PDGFRA, and downstream signaling cascades. Combinatorial approaches, such as combining TKIs with immune checkpoint inhibitors, antiangiogenic agents, or other targeted therapies, offer the potential for enhanced efficacy, delayed resistance, and improved treatment outcomes in GIST patients, including those with refractory or metastatic disease. Additionally, personalized combination regimens tailored to individual patients' molecular profiles and treatment responses present opportunities to optimize therapeutic efficacy and minimize treatment-related toxicities. This opportunity enables pharmaceutical companies and researchers to innovate in the development of more effective and personalized therapeutic strategies for GIST, addressing unmet medical needs and improving clinical outcomes in this challenging disease.

Gastrointestinal Stromal Tumor Therapeutics Market Share Analysis: Avapritinib is the fastest growing market segment over the forecast period to 2030

Avapritinib emerges as the fastest-growing drug in the treatment of gastrointestinal stromal tumors (GIST), owing to its targeted approach and efficacy in addressing specific genetic mutations associated with GIST. Avapritinib is a potent inhibitor of KIT and PDGFRA mutations, which are key drivers of GIST development and progression. Clinical trials have demonstrated promising results in patients with advanced or metastatic GIST harboring these mutations, leading to accelerated approval and adoption of avapritinib in clinical practice. Moreover, avapritinib offers a favorable safety profile and convenient oral administration, enhancing patient compliance and treatment adherence. As healthcare providers increasingly recognize the importance of targeted therapies in improving outcomes for patients with GIST, the demand for avapritinib is expected to continue its rapid growth trajectory. This underscores the pivotal role of targeted therapies like avapritinib in revolutionizing the treatment landscape for GIST, offering new hope for patients and advancing personalized medicine approaches in oncology.

Gastrointestinal Stromal Tumor (GIST) Therapeutics Market Segmentation

By Drug
Imatinib
Ripretinib
Crenolanib
Regorafenib
Avapritinib
Sunitinib
Entrectinib
Larotrectinib
By Therapy
Targeted therapy
Chemotherapy
Radiation therapy
By Distribution Channel
Hospital pharmacies
Retail pharmacies
Online pharmacies
By Route of Administration
Oral
Parenteral
Geographical Analysis
North America (United States, Canada, Mexico)
Europe (Germany, France, United Kingdom, Spain, Italy, Rest of Europe)
Asia Pacific (China, India, Japan, South Korea, Rest of Asia Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East and Africa (Saudi Arabia, UAE, Rest of Middle East, South Africa, Egypt, Rest of Africa)

Gastrointestinal Stromal Tumor (GIST) Therapeutics Companies

AB Science SA
AROG Pharmaceuticals Inc
Bayer AG
Blueprint Medicines Corp
Bristol Myers Squibb Co.
Daiichi Sankyo Co. Ltd
Deciphera Pharmaceuticals Inc
Ipsen Pharma
Mendus AB
Novartis AG
Pfizer Inc
Sun Pharmaceutical Industries Ltd
Theseus Pharmaceuticals.
Xencor Inc
* List not Exhaustive

Reasons to Buy the Gastrointestinal Stromal Tumor (GIST) Therapeutics Market Study

• Deepen your industry insights and navigate uncertainties for strategy formulation, CAPEX, and Operational decisions
• Gain access to detailed insights on the Gastrointestinal Stromal Tumor (GIST) Therapeutics Market, encompassing current market size, growth trends, and forecasts till 2030.
• Access detailed competitor analysis, enabling competitive advantage through a thorough understanding of market players, strategies, and potential differentiation opportunities
• Stay ahead of the curve with insights on technological advancements, innovations, and upcoming trends
• Identify lucrative investment avenues and expansion opportunities within the Gastrointestinal Stromal Tumor (GIST) Therapeutics Industry, guided by robust, data-backed analysis.
• Understand regional and global markets through country-wise analysis, regional market potential, regulatory nuances, and dynamics
• Execute strategies with confidence and speed through information, analytics, and insights on the industry value chain
• Corporate leaders, strategists, financial experts, shareholders, asset managers, and governmental representatives can make long-term planning scenarios and build an integrated and timely understanding of market dynamics
• Benefit from tailored solutions and expert consultation based on report insights, providing personalized strategies aligned with specific business needs.

TABLE OF CONTENTS

1 Introduction to 2024 Gastrointestinal Stromal Tumor (GIST) Therapeutics Market
1.1 Market Overview
1.2 Quick Facts
1.3 Scope/Objective of the Study
1.4 Market Definition
1.5 Countries and Regions Analyzed
1.6 Units, Currency, and Conversions
1.7 Industry Value Chain

2 Research Methodology
2.1 Market Size Estimation
2.2 Sources and Research Methodology
2.3 Data Triangulation
2.4 Assumptions and Limitations

3 Executive Summary
3.1 Global Gastrointestinal Stromal Tumor (GIST) Therapeutics Market Size Outlook, $ Million, 2021 to 2030
3.2 Gastrointestinal Stromal Tumor (GIST) Therapeutics Market Outlook by Type, $ Million, 2021 to 2030
3.3 Gastrointestinal Stromal Tumor (GIST) Therapeutics Market Outlook by Product, $ Million, 2021 to 2030
3.4 Gastrointestinal Stromal Tumor (GIST) Therapeutics Market Outlook by Application, $ Million, 2021 to 2030
3.5 Gastrointestinal Stromal Tumor (GIST) Therapeutics Market Outlook by Key Countries, $ Million, 2021 to 2030

4 Market Dynamics
4.1 Key Driving Forces of Gastrointestinal Stromal Tumor (GIST) Therapeutics Industry
4.2 Key Market Trends in Gastrointestinal Stromal Tumor (GIST) Therapeutics Industry
4.3 Potential Opportunities in Gastrointestinal Stromal Tumor (GIST) Therapeutics Industry
4.4 Key Challenges in Gastrointestinal Stromal Tumor (GIST) Therapeutics Industry

5 Market Factor Analysis
5.1 Value Chain Analysis
5.2 Competitive Landscape
5.2.1 Global Gastrointestinal Stromal Tumor (GIST) Therapeutics Market Share by Company (%), 2023
5.2.2 Product Offerings by Company
5.3 Porter’s Five Forces Analysis
5.4 Pricing Analysis and Outlook

6 Growth Outlook Across Scenarios
6.1 Growth Analysis-Case Scenario Definitions
6.2 Low Growth Scenario Forecasts
6.3 Reference Growth Scenario Forecasts
6.4 High Growth Scenario Forecasts

7 Global Gastrointestinal Stromal Tumor (GIST) Therapeutics Market Outlook by Segments
7.1 Gastrointestinal Stromal Tumor (GIST) Therapeutics Market Outlook by Segments, $ Million, 2021- 2030
By Drug
Imatinib
Ripretinib
Crenolanib
Regorafenib
Avapritinib
Sunitinib
Entrectinib
Larotrectinib
By Therapy
Targeted therapy
Chemotherapy
Radiation therapy
By Distribution Channel
Hospital pharmacies
Retail pharmacies
Online pharmacies
By Route of Administration
Oral
Parenteral
8 North America Gastrointestinal Stromal Tumor (GIST) Therapeutics Market Analysis and Outlook To 2030
8.1 Introduction to North America Gastrointestinal Stromal Tumor (GIST) Therapeutics Markets in 2024
8.2 North America Gastrointestinal Stromal Tumor (GIST) Therapeutics Market Size Outlook by Country, 2021-2030
8.2.1 United States
8.2.2 Canada
8.2.3 Mexico
8.3 North America Gastrointestinal Stromal Tumor (GIST) Therapeutics Market size Outlook by Segments, 2021-2030
By Drug
Imatinib
Ripretinib
Crenolanib
Regorafenib
Avapritinib
Sunitinib
Entrectinib
Larotrectinib
By Therapy
Targeted therapy
Chemotherapy
Radiation therapy
By Distribution Channel
Hospital pharmacies
Retail pharmacies
Online pharmacies
By Route of Administration
Oral
Parenteral
9 Europe Gastrointestinal Stromal Tumor (GIST) Therapeutics Market Analysis and Outlook To 2030
9.1 Introduction to Europe Gastrointestinal Stromal Tumor (GIST) Therapeutics Markets in 2024
9.2 Europe Gastrointestinal Stromal Tumor (GIST) Therapeutics Market Size Outlook by Country, 2021-2030
9.2.1 Germany
9.2.2 France
9.2.3 Spain
9.2.4 United Kingdom
9.2.4 Italy
9.2.5 Russia
9.2.6 Norway
9.2.7 Rest of Europe
9.3 Europe Gastrointestinal Stromal Tumor (GIST) Therapeutics Market Size Outlook by Segments, 2021-2030
By Drug
Imatinib
Ripretinib
Crenolanib
Regorafenib
Avapritinib
Sunitinib
Entrectinib
Larotrectinib
By Therapy
Targeted therapy
Chemotherapy
Radiation therapy
By Distribution Channel
Hospital pharmacies
Retail pharmacies
Online pharmacies
By Route of Administration
Oral
Parenteral
10 Asia Pacific Gastrointestinal Stromal Tumor (GIST) Therapeutics Market Analysis and Outlook To 2030
10.1 Introduction to Asia Pacific Gastrointestinal Stromal Tumor (GIST) Therapeutics Markets in 2024
10.2 Asia Pacific Gastrointestinal Stromal Tumor (GIST) Therapeutics Market Size Outlook by Country, 2021-2030
10.2.1 China
10.2.2 India
10.2.3 Japan
10.2.4 South Korea
10.2.5 Indonesia
10.2.6 Malaysia
10.2.7 Australia
10.2.8 Rest of Asia Pacific
10.3 Asia Pacific Gastrointestinal Stromal Tumor (GIST) Therapeutics Market size Outlook by Segments, 2021-2030
By Drug
Imatinib
Ripretinib
Crenolanib
Regorafenib
Avapritinib
Sunitinib
Entrectinib
Larotrectinib
By Therapy
Targeted therapy
Chemotherapy
Radiation therapy
By Distribution Channel
Hospital pharmacies
Retail pharmacies
Online pharmacies
By Route of Administration
Oral
Parenteral
11 South America Gastrointestinal Stromal Tumor (GIST) Therapeutics Market Analysis and Outlook To 2030
11.1 Introduction to South America Gastrointestinal Stromal Tumor (GIST) Therapeutics Markets in 2024
11.2 South America Gastrointestinal Stromal Tumor (GIST) Therapeutics Market Size Outlook by Country, 2021-2030
11.2.1 Brazil
11.2.2 Argentina
11.2.3 Rest of South America
11.3 South America Gastrointestinal Stromal Tumor (GIST) Therapeutics Market size Outlook by Segments, 2021-2030
By Drug
Imatinib
Ripretinib
Crenolanib
Regorafenib
Avapritinib
Sunitinib
Entrectinib
Larotrectinib
By Therapy
Targeted therapy
Chemotherapy
Radiation therapy
By Distribution Channel
Hospital pharmacies
Retail pharmacies
Online pharmacies
By Route of Administration
Oral
Parenteral
12 Middle East and Africa Gastrointestinal Stromal Tumor (GIST) Therapeutics Market Analysis and Outlook To 2030
12.1 Introduction to Middle East and Africa Gastrointestinal Stromal Tumor (GIST) Therapeutics Markets in 2024
12.2 Middle East and Africa Gastrointestinal Stromal Tumor (GIST) Therapeutics Market Size Outlook by Country, 2021-2030
12.2.1 Saudi Arabia
12.2.2 UAE
12.2.3 Oman
12.2.4 Rest of Middle East
12.2.5 Egypt
12.2.6 Nigeria
12.2.7 South Africa
12.2.8 Rest of Africa
12.3 Middle East and Africa Gastrointestinal Stromal Tumor (GIST) Therapeutics Market size Outlook by Segments, 2021-2030
By Drug
Imatinib
Ripretinib
Crenolanib
Regorafenib
Avapritinib
Sunitinib
Entrectinib
Larotrectinib
By Therapy
Targeted therapy
Chemotherapy
Radiation therapy
By Distribution Channel
Hospital pharmacies
Retail pharmacies
Online pharmacies
By Route of Administration
Oral
Parenteral
13 Company Profiles
13.1 Company Snapshot
13.2 SWOT Profiles
13.3 Products and Services
13.4 Recent Developments
13.5 Financial Profile
List of Companies
AB Science SA
AROG Pharmaceuticals Inc
Bayer AG
Blueprint Medicines Corp
Bristol Myers Squibb Co.
Daiichi Sankyo Co. Ltd
Deciphera Pharmaceuticals Inc
Ipsen Pharma
Mendus AB
Novartis AG
Pfizer Inc
Sun Pharmaceutical Industries Ltd
Theseus Pharmaceuticals.
Xencor Inc
14 Appendix
14.1 Customization Offerings
14.2 Subscription Services
14.3 Related Reports
14.4 Publisher Expertise

By Drug
Imatinib
Ripretinib
Crenolanib
Regorafenib
Avapritinib
Sunitinib
Entrectinib
Larotrectinib
By Therapy
Targeted therapy
Chemotherapy
Radiation therapy
By Distribution Channel
Hospital pharmacies
Retail pharmacies
Online pharmacies
By Route of Administration
Oral
Parenteral